When Youling Sun was diagnosed in Shanghai, China, with acute myeloid leukemia (AML) in 2018, he called his son, Conghao, in Boston, for advice. His son’s message was unequivocal: Come to Boston for your treatment.
Today, Sun, a retired office worker from Shanghai, has multiple reasons to be thankful he took that advice — both for his initial treatment, which put the disease into remission, and, when it relapsed, for a clinical trial at Dana-Farber of a new agent that has kept his cancer at undetectable levels for more than two years.
